Julia Hedrick

Financial Controller at Mesoblast Limited - New York, NY, US

Julia Hedrick's Colleagues at Mesoblast Limited
Jodie Wehling

Vice President of Managed Markets

Contact Jodie Wehling

Niva Sivakumar

Senior Legal Counsel and Company Secretary at Mesoblast

Contact Niva Sivakumar

Suman Abraham

Associate Director, Research

Contact Suman Abraham

Suzan Lourdes

Business Partner, Singapore Operations

Contact Suzan Lourdes

View All Julia Hedrick's Colleagues
Julia Hedrick's Contact Details
HQ
212-880-2060
Location
Melbourne,Victoria,Australia
Company
Mesoblast Limited
Julia Hedrick's Company Details
Mesoblast Limited logo, Mesoblast Limited contact details

Mesoblast Limited

New York, NY, US • 100 - 249 Employees
BioTech/Drugs

Mesoblast (ASX:MSB; Nasdaq:MESO) is developing and commercializing allogeneic cellular medicines to treat serious and life-threatening inflammatory diseases with significant, unmet medical needs.The Company's Phase 3 off-the-shelf mesenchymal lineage cell product candidates are:• RYONCIL™ (remestemcel-L) for steroid-refractory acute graft versus host disease (acute GVHD)• Remestemcel-L for moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 infection• REVASCOR® for advanced chronic heart failure, and• MPC-06-ID for chronic low back pain due to degenerative disc disease.The US FDA has accepted for priority review Mesoblast's BLA to seek approval of RYONCIL to treat acute GVHD in children and set a PDUFA action date of September 30, 2020.The Company's proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide.Mesoblast's approach to product development is to ensure rigorous scientific investigations are performed with well-characterized cell populations in order to understand mechanisms of action for each potential indication. Extensive preclinical translational studies guide clinical trials that are structured to meet stringent safety and efficacy criteria set by international regulatory agencies. All trials are conducted under the continuing reviewof independent Data Safety Monitoring Boards comprised of independent medical experts and statisticians. Mesoblast has an extensive patent portfolio comprising approximately 1,000 patents and patent applications with protection extending through 2040 in all major markets. This intellectual property portfolio covers composition of matter, manufacturing, and therapeutic applications of mesenchymal lineage cells. The Company believes this patent estate provides strong global protection.

Cell-based therapies cellular medicines Mesenchymal Lineage Adult Stem Cells regenerative medicine Biotech
Details about Mesoblast Limited
Frequently Asked Questions about Julia Hedrick
Julia Hedrick currently works for Mesoblast Limited.
Julia Hedrick's role at Mesoblast Limited is Financial Controller.
Julia Hedrick's email address is ***@mesoblast.com. To view Julia Hedrick's full email address, please signup to ConnectPlex.
Julia Hedrick works in the Research industry.
Julia Hedrick's colleagues at Mesoblast Limited are Jodie Wehling, Jack Hayes, Jeremy Clarke, Justin Santiano, Niva Sivakumar, Suman Abraham, Suzan Lourdes and others.
Julia Hedrick's phone number is 212-880-2060
See more information about Julia Hedrick